Skip to main content
Signal8

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week

$KYMRPress releaseMay 5, 2026, 7:00 AM ETRead the release

Kymera Therapeutics presented new preclinical data at Digestive Disease Week showing its first-in-class oral IRF5 degrader KT-579 outperformed standard therapies in IBD models. The data demonstrated broad suppression of inflammatory cytokines and protection against weight loss comparable to JAK inhibitors and anti-TNF agents. The Phase 1 healthy volunteer trial for KT-579 is currently ongoing, with initial data expected in the second half of 2026. The study aims to confirm robust degradation of IRF5 at safe and well-tolerated doses.

Key figures

Drug Name
KT-579
Phase Of Trial
Phase 1

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $40.67/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    KYMR: Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week — AI Analysis | Signal8